Champions Oncology, Inc. - CSBR STOCK NEWS

Champions Oncology (NASDAQ:CSBR) and Cyclica have announced a new therapeutic development partnership aimed at creating a small molecule drug discovery program. This initiative will focus on therapeutic targets linked to various solid tumors, including non-small cell lung cancer and head and neck cancer. Champions will lead the program, co-owning it with Cyclica, and is expected to make milestone and royalty payments upon achieving specific goals. Both companies emphasize the potential for improving patient outcomes through innovative drug discovery.

Champions Oncology, Inc. (NASDAQ:CSBR) announced its Lumin Bioinformatics Platform has been selected as a finalist for the 'Best in Show' Competition at the Bio-IT World Conference & Expo. The demonstration will take place on May 4th. Lumin is a powerful tool that provides access to over 2 billion data points from more than 12,000 cancer patients, enabling advanced analytics and integration of user data. CEO Ronnie Morris emphasized the platform's evolving capabilities and its role in transforming cancer research and biomarker discovery.

Champions Oncology, Inc. (Nasdaq:CSBR) reported a record quarterly revenue of $13.2 million for Q3 of fiscal 2022, reflecting a 22% year-over-year increase. Despite increased operating costs of $12.4 million, the company achieved an adjusted EBITDA of $1.5 million. Gross margin improved to 51.4% over the nine months ended January 31, 2022, while net income from operations stood at $830,000. With strong cash reserves of $8.7 million and no debt, Champions continues to invest in strategic partnerships and therapeutic discovery.

Champions Oncology (CSBR) will release its third quarter financial results on March 15, 2022, after market close. The company, known for its AI-driven approach in drug discovery, will hold a conference call at 4:30 P.M. EDT to discuss these results. Interested parties can join the call using specific dial-in numbers. Champions Oncology is focused on cancer therapeutics and R&D services, leveraging innovative technologies to transform drug development.

Champions Oncology (NASDAQ:CSBR) has announced a strategic partnership with GigaMune to co-develop advanced T cell therapies and cancer diagnostics. The collaboration aims to utilize Champions' Autologous Tumor Infiltrating Lymphocyte (TIL) platform alongside GigaMune's T Cell Receptor (TCR) Discovery technology to identify novel TCR sequences. This effort seeks to create unique libraries of TCRs for clinical applications, focusing on solid tumor indications. Champions will retain rights for selected TCRs while jointly owning the remaining libraries for further commercialization.

Champions Oncology, Inc. (CSBR) has announced a new therapeutic co-development partnership with Fannin Innovation Studio. This collaboration aims to combine Champions' Lumin platform with Fannin's Raptamer platform to create next-generation Raptamer Drug Conjugates (RDCs), specifically targeting tumors such as non-small cell lung cancer and head and neck cancer. The partnership will share ownership of developments and initiate a joint venture after meeting specific milestones. The collaboration harnesses AI-driven analytics and unique platforms to expedite clinical evaluation of novel therapeutic targets.

Champions Oncology (Nasdaq:CSBR) and Alloy Therapeutics have announced a new partnership aimed at developing therapeutic monoclonal antibodies for use in next-generation Antibody Drug Conjugates (ADCs). The collaboration will leverage Champions' Lumin platform for innovative drug discovery, focusing initially on a target linked to hematologic tumors such as Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM). Champions will retain ownership of the developed therapeutic molecule, while Alloy will receive milestone and royalty payments.

Champions Oncology, a global biotech leader, reported a record revenue of $11.8 million for Q2 of fiscal 2022, marking a 17% year-over-year increase.

The company posted a net income from operations of $263,000 and a non-GAAP income of $743,000. Gross margin improved to 52%, driven by reduced reliance on outsourcing.

R&D expenses surged by 39.3% to support new therapeutic targets, while sales and marketing costs rose by 21.7%. The company ended the quarter with a solid cash position of $4.8 million.

Champions Oncology, Inc. (CSBR) will report its financial and operational results for the second quarter ended October 31, 2021, on December 13, 2021, after market close. A conference call is scheduled for the same day at 4:30 P.M. EST to discuss the results. Interested participants can join the call via specific dial-in numbers provided in the release. Champions Oncology is known for its transformative technology solutions in oncology drug discovery and development, focusing on data-driven research methodologies.